Lixisenatide shows efficacy in type 2 diabetes management

04/5/2012 | Medscape (free registration)

A higher proportion of drug-naive type 2 diabetes patients achieved blood glucose levels lower than 7% with once-daily lixisenatide for 12 weeks compared with those who received placebo treatment, researchers reported in Diabetes Care. Lixisenatide-treated patients also had bigger drops in two-hour postprandial glucose levels than those in the placebo group, researchers noted.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA